

CURRICULUM VITAE

JOHN WESLEY MCCONNELL, M.D.
Kentuckiana Pulmonary Associates
100 W. Market Street, Suite 2
Louisville, KY 40202

EDUCATION

- 1976 Bachelor of Science, University of Georgia, Athens, Georgia
- 1982 M.D., Medical College of Georgia, Augusta, Georgia
- 1982-83 Intern, University of Kentucky, Lexington, Kentucky
- 1983-85 Resident, Internal Medicine, University of Kentucky, Lexington, Kentucky
- 1985-87 Pulmonary Fellow, University of Kentucky, Lexington, Kentucky

PROFESSIONAL APPOINTMENTS

- 1987-89 Asst. Professor of Medicine, University of Kentucky, Lexington, Kentucky
- 1988-89 Staff Physician, Veterans Administration Medical Center, Lexington, Kentucky
- 1992 President, Kentucky Thoracic Society
- 1994-2010 Medical Director, Lung Transplant Program, Jewish Hospital, Louisville, Kentucky
- 1995-98 Medical Director, Pulmonary Services, Vencor Hospital, Louisville, Kentucky
- 1995-96 President, Medical Staff, Vencor Hospital, Louisville, Kentucky
- 1995-2002 Chapter Representative, American Thoracic Society, State of Kentucky
- 1995-97 Representative, American College of Chest Physicians, State Of Kentucky Political Liaison
- 1998-present Medical Director, Kindred Hospital

- 2000-present Medical Advisory Board, Kindred Healthcare
- 2000-present Member, Hospital Division Quality Council, Kindred Healthcare
- 2001-2009 Chairman of Board, Jewish Hospital Heart and Lung Institute
- 2001-05 Board of Directors, Jewish Hospital
- 2007-2012 Medical Director, Respiratory Therapy, Jewish & St. Mary's Healthcare
- 2007-2011 Director of Quality, Critical Care, Jewish & St. Mary's Healthcare
- 2012-present Clinical Director of Pulmonary Transplant, University of Kentucky

OTHER EMPLOYMENT PERTAINING TO CURRENT APPOINTMENTS

- 1988-89 Assoc. Director, Intensive Care Unit, University of Kentucky College of Medicine, Lexington, Kentucky
- 1989-98 Partner, Pulmonary & Internal Assoc., PSC, Louisville, Kentucky
- 1995-97 President, Pulmonary & Internal Assoc., PSC, Louisville, Kentucky
- 1998-present Partner, Kentuckiana Pulmonary Associates, Louisville, Kentucky
- 2003-2009 President, Kentuckiana Pulmonary Associates, Louisville, Kentucky
- 2005-present Director, Pulmonary Hypertension Center, Kentuckiana Pulmonary Associates, Louisville, Kentucky
- 2016-present President, Kentuckiana Pulmonary Research Center, Louisville, Kentucky

CERTIFICATION AND LICENSURE

Kentucky License # 22726
 Kentucky DEA AM2192045
 Indiana License # 01037829
 Indiana CSC 01037829B
 American Board of Int. Medicine
 American Board of I.M. (Pulmonary)

PROFESSIONAL AFFILIATIONS

American Thoracic Society
Jefferson County Medical Society
Kentucky Medical Society
American College of Chest Physicians
Kentucky Thoracic Society
American Society of Internal Medicine
Southern Medical Association
American College of Occupational & Environmental Medicine
American Medical Society
American Lung Association of Kentucky

AREAS OF RESEARCH INTEREST

Pulmonary Hypertension
Lung Transplant
High altitude
Sleep Apnea
Acute and chronic effects of hypoxemia
Hyperbaric Medicine

CONSULTANT AND SPEAKER ACTIVITIES

Actelion Pharmaceuticals US, Inc.
United Therapeutics Corporation
Simply Speaking, sponsored by Gilead
Boehringer Ingelheim
Forest Pharmaceuticals
Bayer Pharmaceuticals
Genentech , Inc.
Reata Pharmaceuticals

COLLEGIATE AND UNIVERSITY COMMITTEES

| | |
|---------|---|
| 1988-89 | Ad Hoc Committee for Internal Residency Program, Department of Medicine |
| 1988-89 | Interim Chairman, Respiratory Therapy Committee |

BIBLIOGRAPHY

Articles Published or In Press:

Phillips BA, McConnell JW, Smith M.D.: The effects of hypoxemia on cardiac output: A dose response curve. Chest 1988; 93(3):471-75.

Berry D, McConnell JW, Phillips BA, Carswell C, Lamb D, Prine B: Isocapnic hypoxemia and neuropsychological functioning. J Clin Exposure Neuropsych. In Press.

Berger R, Phillips B, McConnell JW, Overman TL: Safety and clinical efficacy of nebulized anesthesia for the obtention of peripheral and endobronchial cultures. Chest 1989; 95:299-303

Tolge C, Vasudeva I, McConnell JW: Phrenic Nerve Palsy Accompanying Chiropractic Manipulation of the Neck. So Med Journal 1993; 86(6): 668-690.

McClave SA, Lowen CC, Kleber MJ, Nicholson JF, Jimmerson SC, McConnell JW, Jung Y: Are Patients Fed Appropriately According to Their Caloric Requirements? In Press.

Burki NK, McConnell JW, Ayub M, Liles RM: Effects of Acute Prolonged Exposure to High-Altitude Hypoxia on Exercise-Induced Breathlessness. Clinical Science (1999) 96, 327-333.

Abstracts:

Berger R, Phillips BA, McConnell JW: Reliability and reproducibility of peripheral endobronchial cultures. Chest 1986;98 (Suppl).

McConnell JW, Berger R, Overman T: Impact of transporting technique on the bacterial yield from microbiology bushes. Am Rev Respir Dis 1988; 137(4):177.

Berger R, McConnell JW, Phillips B: Diagnostic value of the gram stain of unexpected sputum in bacterial pneumonias. A pilot study. Am Rev Respir Dis 1988; 137(4):219.

Burki NK, Liles R, McConnell JW: Exercise capacity following acute exposure to high altitude. The Physiologist 1988. In Press.

Anstead M, Hunt T, McConnell JW, Burki NK: Effects of Inhaled Albuterol on Beta-2 Adrenergic Receptor Density in Stable Asthmatics and Normal Subjects. Res and Crit Care Med 1997; 155(4): A855.

Kleber MJ, Lowen CC, McClave SA, Miller RK, McConnell JW, Jimmerson SC, Nicholson JF, Jung LY: Indirect Calorimetry (IC): Is It Required to Maximize Patient Outcome from Nutritional Alimentation? Am Physiologist Soc 1997. In Press.

Anstead, MI, Hunt TA, McConnell, JW, Nausherwan KB: Effects of Therapeutic Doses of Albuterol on B2-Adrenergic Receptor Density and Metabolic Changes. Journal of Asthma Volume 38, Issue I, Jan 2001

McConnell, JW, Holtman, C, Hobbs, K: Transition from Epoprostenol Infusion to Inhaled Iloprost in Patient with Primary Pulmonary Hypertension, American College of Chest Physicians, October 2006.

McConnell, J. W., Nathan, S., Hobbs, K., Villanueva, D., Hartline, B., and Frantz, R. A multicenter, retrospective study of patients with pulmonary arterial hypertension who received inhaled iloprost for more than one year. CHEST, October, 2011. (Abstract and poster presentation)

Oudiz R, Meyer C, Chin M, Feldman J, Goldsberry A, McConnell J, McCullough P, O'Grady M, Tapson V, Torres F, Waxman A, and White J. Bardoxolone Methyl Evaluation in Patients with Pulmonary Arterial Hypertension. CHEST, October 2015. (Abstract and slide presentation)

Boeckenhoff A, Coghlan J, Denton CP, Ghofrani H-A, Grimminger F, He J, Humber M, McConnell, JW, Meier C, Pena J, Riemekasten G, Vizza CD. Efficacy and safety of Riociguat in patients with pulmonary arterial hypertension associated with connective tissue disease. PHA, June 2016. (Abstract and poster presentation)

McConnell J, Engel P, Franz R, Rosenkranz S, Vizza CD, Fritsch A, Pena J, Ghofrani H-A. Effects of Riociguat in treatment-naïve vs pretreated patients with pulmonary arterial hypertension (PAH): 2-year efficacy results from the PATENT-2 study. CHEST, October 2016 (Abstract and slide presentation)

Krishnan S, Robinson K, McConnell JW. Non-physician Factors Affecting Use of Prostacyclins in Pulmonary Hypertension Patients with Advanced Functional Class. CHEST, October 2016. (Abstract and poster presentation)

Rahaghi F, Alnuaimat H, Awdish R, Balasubramanian V, Bourge R, Burger C, Butler J, Cauthen C, Chakinala M, deBoisBlanc B, Eggert M, Engel P, Feldman J, McConnell J, Park M, Sager J, Sood N, and Palevsky H. Delphi Consensus Recommendations for the Clinical Management of Patients Receiving Macitentan for Pulmonary Arterial Hypertension (PAH). CHEST, October 2016. (Abstract and slide presentation)

Oudiz R, Meyer C, Chin M, Feldman J, Goldsberry A, McConnell J, McCullough PA, O'Grady M, Tapson V, Torres F, Waxman AB, White RJ. Bardoxolone Methyl

Produces Durable Benefits in Participants with Pulmonary Arterial Hypertension: Data from an Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2106; 68 (suppl 10).

Oudiz R, Meyer C, Chin M, Feldman J, Goldsberry A, McConnell J, McCullough P, O'Grady M, Tapson V, Torres F, Waxman A, White J. Results of Interim Analysis of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD) (The LARIAT Study). American Journal of Respiratory and Critical Care Medicine 2017; 195: A6896.

De Jesus Perez V, Badesch D, Zamanian R, Fineman J, Klinge J, Ford J, McConnell J, Sager J, Feldman J, Shlobin O, Grinnan D, Bull T, Rosenzweig E, Santos L, Chakinala M, Elwing J, Frantz R, DeMarco T. Characterization of Hispanics with Pulmonary Hypertension Association Registry. ATS International Meeting, May 2017 (Abstract and Poster presentation)

RESEARCH STUDIES (Primary Investigator)

Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry); Actelion Pharmaceuticals

COMPASS-3 Trial; Actelion Pharmaceuticals, closed

Prowess-15 Trial; Actelion Pharmaceuticals, closed

COPD Trial; Altana, closed

INHALE 15 Trial; Actelion Pharmaceuticals, closed

RESPIRE Registry; Actelion Pharmaceuticals, closed

ARTEMIS Trial; Gilead Pharmaceuticals, closed

Seraphin Trial; Actelion Pharmaceuticals, closed

FREEDOM Trials; United Therapeutics

B1321001, B1321002, and B1321003; Pfizer, closed

ARTEMIS-PH Trial; Gilead Pharmaceuticals, closed

GRIPHON trial; Actelion Pharmaceuticals, closed

PROSPECT registry; Actelion Pharmaceuticals, closed

Transition study; Actelion Pharmaceuticals, closed

One Year Study; Actelion Pharmaceuticals, closed

PATENT 1 and 2; Bayer HealthCare, closed

Aspire Registry; United Therapeutics, closed

PAH Queri; Actelion Pharmaceuticals

Bronchiectasis Study, Gilead Pharmaceuticals, closed

AIR01-CS05,AIR01-CS06, Aires Pharmaceuticals, Inc., closed

Ikaria Pharmaceuticals

Boehringer Ingelheim 205.447

MedImmune IPF

Gilead RANIER

Actelion/UBC, PRO for PAH

Symphony, Actelion Pharmaceuticals

Integrated Diagnostics, Lung Nodule Study

Actelion, MERIT

Actelion, MELODY

Actelion OPUS Registry

Reata Lariat, Catalyst

Actelion, TRANSIT

Actelion, TRITON

Actelion, Portico

Eiger Liberty

Lung RX, BEAT

United Therapeutics